^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FGFR2-INA fusion

    i
    Other names: FGFR2, BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25, Fibroblast growth factor receptor 2, INA, Internexin Neuronal Intermediate Filament Protein Alpha, 66 KDa Neurofilament Protein, Alpha-Internexin, Alpha-Inx, NF-66, NEF5, Internexin Neuronal Intermediate Filament Protein, Alpha, Neurofilament-66, Tax-Binding Protein, Neurofilament 5 (66kD), Neurofilament-66, Neurofilament 5, TXBP-1
    Entrez ID:
    2263; 9118
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over1year
    Clinical impact of FGFR inhibitors on FGFR2 positive pancreatic cancer (AACR 2023)
    Patient 1 harbored an FGFR2-USP33 fusion and exhibited a partial response to pemigatinib for 25 months following progression on gemcitabine/abraxane and FOLFIRI chemotherapy. Patient 2 harbored an FGFR2-INA fusion with 12 months of stable disease to pazopanib after experiencing progression from chemotherapy... This retrospective analysis provides clinical evidence that there is a subpopulation of KRAS wild-type FGFR2 fusion positive pancreatic patients who can have beneficial and lasting responses to FGFR inhibitors further suggesting a need to investigate and expand the availability of FGFR inhibitors to more cancer types.
    Clinical • Tumor mutational burden • MSi-H Biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • CA 19-9 (Cancer antigen 19-9) • CEP55 (Centrosomal Protein 55)
    |
    MSI-H/dMMR • FGFR2 mutation • KRAS wild-type • FGFR2 fusion • RAS wild-type • FGFR fusion • FGFR2-INA fusion • FGFR wild-type • FGFR2 wild-type
    |
    gemcitabine • 5-fluorouracil • Iclusig (ponatinib) • pazopanib • albumin-bound paclitaxel • Truseltiq (infigratinib) • irinotecan • Pemazyre (pemigatinib) • leucovorin calcium
    4years
    [VIRTUAL] Polymorphous Low-Grade Neuroepithelial Tumor of the Young: Molecular Profiling Reveals an Additional Case With an FGFR2-INA Fusion (CAP 2020)
    A CHEK2 mutation, which was likely germline in origin, was also observed. This case further supports the notion that PLNTY is characterized by MAPK pathway activation and suggests that chromosomal instability may also play a role in PLNTY molecular biology.
    Clinical
    |
    BRAF (B-raf proto-oncogene) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • FGFR3 (Fibroblast growth factor receptor 3) • CHEK2 (Checkpoint kinase 2) • CD34 (CD34 molecule) • GFAP (Glial Fibrillary Acidic Protein)
    |
    FGFR2 fusion • CHEK2 mutation • IDH1 R132H • FGFR2-INA fusion